Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Publication year range
1.
Eur J Gynaecol Oncol ; 18(3): 173-6, 1997.
Article in English | MEDLINE | ID: mdl-9174829

ABSTRACT

To assess the efficacy and the compliance of weekly cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer, 23 patients, FIGO stage IB-IIA > 4 cm-IIB, were recruited. Treatment consisted of four weekly courses of cisplatin (1.5 mg/kg): 91% of the patients received the planned therapy without dose reduction or delay. Toxicity was mild: delayed emesis was the most common side effect. Overall clinical response rate was 85% with a complete response in 28%. Nineteen patients underwent surgery without any undue increase in morbidity. Histologic analysis of surgical specimens revealed a complete response in 25% of stage IB-IIA patients; in only one case of stage IIB, was residual parametrial involvement present. In conclusion, weekly cisplatin is highly effective, with lower cost and less toxicity compared to other neoadjuvant chemotherapy regimens.


Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Agents/administration & dosage , Carcinoma, Squamous Cell/drug therapy , Cisplatin/administration & dosage , Uterine Cervical Neoplasms/drug therapy , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Adult , Aged , Antineoplastic Agents/adverse effects , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/surgery , Chemotherapy, Adjuvant , Cisplatin/adverse effects , Disease-Free Survival , Drug Administration Schedule , Female , Humans , Middle Aged , Neoplasm Metastasis , Neoplasm Staging , Pilot Projects , Prospective Studies , Survival Rate , Treatment Outcome , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...